论文部分内容阅读
文章简介癌基因MYCN(编码N-Myc)在癌症中出现扩增突变预示不良预后和复发耐药。众多细胞水平和模式动物研究表明,干预癌蛋白N-Myc的表达或活性能够显著甚至完全抑制肿瘤发生和发展。然而,目前尚无直接靶向转录因子N-Myc的药物,寻找替代策略间接抑制N-Myc势在必行。本研究首次发现Polo样激酶1(PLK1)与癌蛋白
Article Introduction The amplification of the oncogene MYCN (encoding N-Myc) in cancers predicts poor prognosis and recurrent drug resistance. Numerous cellular levels and patterns Animal studies have shown that interfering with the expression or activity of oncoprotein N-Myc can significantly or even completely inhibit tumorigenesis and progression. However, there is no drug that directly targets the transcription factor N-Myc and it is imperative to find alternative strategies to indirectly inhibit N-Myc. This study first found Polo-like kinase 1 (PLK1) and oncoprotein